Cost analysis of magnetically controlled growing rods compared with traditional growing rods for early-onset scoliosis in the US: an integrated health care delivery system perspective

David W Polly Jr, Stacey Jackerman, Karen Schneider, Jeff B Pawelek, Behrooz A Akbarnia

1Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, MN, 2Covance Market Access Services Inc., San Diego, CA, USA; 3Covance Market Access Services Inc., Sydney, Australia; 4San Diego Spine Foundation, San Diego, CA, USA

Purpose: Traditional growing rod (TGR) for early-onset scoliosis (EOS) is effective but requires repeated invasive surgical lengthenings under general anesthesia. Magnetically controlled growing rod (MCGR) is lengthened noninvasively using a hand-held magnetic external remote controller in a physician office; however, the MCGR implant is expensive, and the cumulative cost savings have not been well studied. We compared direct medical costs of MCGR and TGR for EOS from the US integrated health care delivery system perspective. We hypothesized that over time, the MCGR implant cost will be offset by eliminating repeated TGR surgical lengthenings.

Methods: For both TGR and MCGR, the economic model estimated the cumulative costs for initial implantation, lengthenings, revisions due to device failure, surgical-site infections, device exchanges (at 3.8 years), and final fusion, over a 6-year episode of care. Model parameters were estimated from published literature, a multicenter EOS database of US institutions, and interviews. Costs were discounted at 3.0% annually and represent 2015 US dollars.

Results: Of 1,000 simulated patients over 6 years, MCGR was associated with an estimated 270 fewer deep surgical-site infections and 197 fewer revisions due to device failure compared with TGR. MCGR was projected to cost an additional $61 per patient over the 6-year episode of care compared with TGR. Sensitivity analyses indicated that the results were sensitive to changes in the percentage of MCGR dual rod use, months between TGR lengthenings, percentage of hospital inpatient (vs outpatient) TGR lengthenings, and MCGR implant cost.

Conclusion: Cost neutrality of MCGR to TGR was achieved over the 6-year episode of care by eliminating repeated TGR surgical lengthenings. To our knowledge, this is the first cost analysis comparing MCGR to TGR – from the US provider perspective – which demonstrates the efficient provision of care with MCGR.

Keywords: early-onset scoliosis, magnetically controlled growing rods, economic model, cost analysis, traditional growing rods

Introduction

Early-onset scoliosis (EOS) is characterized by curvature of the spine >10°, appearing before the age of 10 years.1 EOS can be defined as idiopathic, congenital, neuromuscular, or associated with various syndromes.2–4 If untreated, EOS can progress to cause significant disfigurement and chest wall deformity, with the potential for worsening pulmonary insufficiency and poor quality of life.3
Treatment aims to monitor and assist thoracic development, focusing on controlling the structural deformity by supporting normal spinal and chest wall growth. Treatment options include casting or bracing, spinal fusion, and growth-friendly surgical techniques. The traditional growing rod (TGR) technique requires periodic surgical lengthenings of the device to maintain curve correction while allowing for continued spinal growth. This technique has proven useful for patients with progressive and severe curves, or for growing children for whom a delay to fusion is required to allow spine and thoracic development. The primary disadvantages of TGR are the risks associated with general anesthetic and wound complications due to repeated invasive surgical procedures. TGR surgery is also associated with substantial socioeconomic, psychological, and health-related quality-of-life (HRQoL) disadvantages for patients and their caregivers. This is due to substantial reductions in patients’ normal activity levels and the indirect costs associated with the time taken from school and work for each invasive procedure.

Recent technical advances have aimed to overcome the drawbacks associated with TGR. In particular, the magnetically controlled growing rod (MCGR) technique is a new technology in which a growing rod, once implanted during an invasive surgical procedure (similar to TGR), is lengthened noninvasively using a hand-held magnetic external remote controller. Using the hand-held remote controller, elongation is performed in millimeters in two ways: continuous and incremental. Continuous mode maximizes lengthening until a set force is achieved (the device’s safety feature stops distraction at ~42 lbs of axial force). The incremental setting allows programmable/custom lengthening based on patient growth chart targets. The amount of lengthening achieved is then confirmed by X-ray. The preclinical and clinical findings of treatment with MCGR have demonstrated MCGR as safe and effective over a follow-up period of up to 2 years. The primary advantage of the MCGR technology, compared with TGR, is that the device can be lengthened noninvasively in the physician office without anesthesia. This eliminates the need for periodic surgeries for lengthening, necessary with TGR, and has potential to reduce long-term medical resource consumption and costs in comparison to TGR and improve the HRQoL for affected children.

The health-related costs associated with the treatment of EOS, using MCGR, have recently been shown to be lower compared with TGR in the European setting, specifically in France and the UK. Charroin et al reported the cumulative cost savings over 4 years to be €6,135 from the French Sickness Fund perspective. These savings were attributed to a reduction in hospital stays, periodic invasive procedures, spinal cord monitoring, anesthesia, and pharmaceutical use. In a second economic study, conducted for the UK by Rolton et al, the estimated cumulative cost savings per child after 5 years of treatment with MCGR compared with TGR was reported to be £8,888. One further economic study, conducted from the US payer perspective, also reported the cumulative cost savings ($39,632 per patient at year 5) for MCGR compared with TGR.

The objective of this research was to perform a cost analysis of MCGR compared with TGR for EOS from the US integrated health care delivery system perspective over the complete 6-year episode of care from initial implantation until final fusion. To our knowledge, this is the first cost analysis of MCGR compared to TGR performed from the provider, as opposed to the payer perspective, and the first such cost analysis that accounts for the complete episode of care. We hypothesized that over time, the higher MCGR implant cost will be offset by eliminating repeated TGR surgical lengthenings, as seen in previous research.

**Materials and methods**

**Model overview**

An economic model was developed using Microsoft Excel to compare the cost of MCGR and TGR, from the perspective of the US integrated health care delivery system. For both TGR and MCGR, the model estimated the cumulative costs associated with initial implantation, surgical revisions, device exchange, rod lengthenings, and final spinal fusion over a 6-year episode of care, from initial implantation to final fusion. The model also accounted for the occurrence of surgical-site infection (SSI; deep and superficial) and device failure.

Model parameters were estimated on the basis of published literature, analyses of a multicenter EOS database comprising the US institutions, and a series of one-on-one interviews conducted with six pediatric spine surgeons, two private payers, and two hospital purchasers. Confidential data of patients of the clinicians/hospital purchasers or of beneficiaries from payers were not obtained or used for any aspect of the cost analysis. Furthermore, interviewees themselves were not being evaluated (ie, clinician and hospital performance were not being evaluated) and, therefore, the interviewees are not considered “subjects” requiring ethics committee approval and subject consent. Rather, the interviewees provided feedback on the model framework, content (assumptions), and relevance. All costs represent 2015 US dollars, and were discounted at an annual rate of 3.0%, as recommended by the Congressional Budget Office. The model framework and clinical parameters are reported in Table 1, and medical resource use is reported in Table 2. Of note, the TGR and MCGR device failure rates...
Magnetic vs traditional growing rod cost analysis

Model assumptions and data sources
Assumptions made in the development of this model include the following: clinical effectiveness (curve correction and increase in thoracic height) is equivalent between MCGR and TGR; resource use between TGR and MCGR with respect to initial implantation, revision, exchange, and final fusion is similar (with the exception of the device cost, where appropriate); one X-ray is required per insertion, lengthening procedure, exchange, revision, deep SSI, and final fusion; all patients for MCGR and TGR require one device exchange surgery at 3.8 years, based on the average spine growth observed in a child aged 6 years; and deep SSI requires a complete replacement of implants, and superficial infection requires oral antibiotics. The components replaced during a partial revision procedure (Table 2) were based on the study of Bess et al and expert clinical advice. Among patients with partial removal, pedicle screw/hooks were assumed to be replaced 95% of the time, rod set screws 61% of the time, and all other components (including rods and connectors) 100% of the time. It was further assumed that MCGR costs were not incurred for partial or complete revisions due to MCGR failure within 1 year following an MCGR implantation or MCGR exchange (in the unlikely event of a manufacturing defect); other costs for the revisions were incurred (eg, hospital facility costs and professional fees). For revisions were obtained from a previously conducted economic evaluation commissioned by the National Institute for Health and Care Excellence, as reported in the external assessment center report and journal publication. These rates were calculated based on the best available evidence.

Table 1 Model framework and clinical parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Base case value (sensitivity analysis [range])</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Model framework</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time horizon (years)</td>
<td>6 (1–6)</td>
<td>15,16</td>
</tr>
<tr>
<td>Size of cohort</td>
<td>Per patient</td>
<td>NA</td>
</tr>
<tr>
<td>Per 1,000 patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Payer mix</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Private payer (%)</td>
<td>51.5 (0–100)</td>
<td>26,27</td>
</tr>
<tr>
<td>Medicaid (%)</td>
<td>48.5 (0–100)</td>
<td></td>
</tr>
<tr>
<td><strong>Discount rate (%) per annum</strong></td>
<td>3.00 (0.00–5.00)</td>
<td>14</td>
</tr>
<tr>
<td><strong>TGR lengthening setting of care</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital outpatient/inpatient (%)</td>
<td>45.8 (0.0–100.0)/54.2 (0.0–100.0)</td>
<td></td>
</tr>
<tr>
<td>Hospital inpatient 1-day short stay (%)</td>
<td>55.5</td>
<td>22</td>
</tr>
<tr>
<td>Hospital inpatient standard ward (%)</td>
<td>35.2</td>
<td></td>
</tr>
<tr>
<td>Hospital inpatient ICU (%)</td>
<td>9.3</td>
<td>Clinical practice data</td>
</tr>
<tr>
<td><strong>MCGR lengthening setting of care</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physician (%)</td>
<td>100.0</td>
<td></td>
</tr>
<tr>
<td><strong>Device failures and SSIs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TGR device failure (% per month)</td>
<td>0.59 (0.20–1.26)</td>
<td>15,16</td>
</tr>
<tr>
<td>MCGR device failure (% per month)</td>
<td>0.37 (0.00–0.59)</td>
<td></td>
</tr>
<tr>
<td>Device failures requiring complete removal (vs partial) (%)</td>
<td>5.8 (2.9–11.6)</td>
<td>18b</td>
</tr>
<tr>
<td>SSI (% per invasive surgery)</td>
<td>2.34 (1.17–4.68)</td>
<td></td>
</tr>
<tr>
<td>Deep SSI (vs superficial) (%)</td>
<td>68 (34–100)</td>
<td>7,8,18,28–35</td>
</tr>
<tr>
<td><strong>Other risk factors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Device failure: single rods (vs dual rods), RR</td>
<td>2.64 (1.32–5.28)</td>
<td>18</td>
</tr>
<tr>
<td>SSI: Medicaid patients (vs all other patients), RR</td>
<td>2.06 (1.19–3.58)</td>
<td>36</td>
</tr>
</tbody>
</table>

Notes: Estimate based on experience at one facility where three of 41 patients (conservatively, ~5%) had an ICU stay, whereby half were undergoing the lengthening on an inpatient basis and the other half on an outpatient basis. *Clinical advisors.

Abbreviations: ICU, intensive care unit; MCGR, magnetically controlled growing rod; NA, not applicable; RR, relative risk; SSI, surgical site infection; TGR, traditional growing rod.

Table 2 Resource use

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Base case value (sensitivity analysis [range])</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Months between MCGR lengthenings</td>
<td>3.0 (1.0–6.0)</td>
<td>15,16</td>
</tr>
<tr>
<td>Months between TGR lengthenings</td>
<td>6.0 (6.0–12.0)</td>
<td>37</td>
</tr>
<tr>
<td>Percentage of dual rods (%)</td>
<td>85.0 (0.0–100.0)</td>
<td>22b</td>
</tr>
<tr>
<td>Years to implant exchange</td>
<td>3.8 (3.0–5.0)</td>
<td>17b</td>
</tr>
<tr>
<td>Wedding band use for TGR single-rod constructs (%)</td>
<td>15.00</td>
<td>22b</td>
</tr>
<tr>
<td>Tandem connector use for TGR single-rod constructs (%)</td>
<td>47.00</td>
<td></td>
</tr>
<tr>
<td>Wedding band use for TGR dual-rod constructs (%)</td>
<td>28.00</td>
<td></td>
</tr>
<tr>
<td>Tandem connector use for TGR dual-rod constructs (%)</td>
<td>67.00</td>
<td></td>
</tr>
<tr>
<td>Cross link use for TGR dual-rod constructs (%)</td>
<td>86.00</td>
<td></td>
</tr>
<tr>
<td>Cross link use for MCGR dual-rod constructs (%)</td>
<td>86.00</td>
<td>22b</td>
</tr>
</tbody>
</table>

Note: *Clinical advisors.

Abbreviations: MCGR, magnetically controlled growing rod; TGR, traditional growing rod.
due to anchor or foundation issues within 1 year following an MCGR implantation or MCGR exchange, it was assumed that the MCGRs did not require replacement.

Hospital inpatient facility costs were based on Medicare payments (diagnosis-related group [DRG] data), physician professional fees were based on current procedural terminology data, and hospital outpatient facility costs were based on ambulatory payment classification data. Because bundled DRG payments include the TGR device cost, for MCGR hospital inpatient procedures, the TGR device costs were subtracted from the DRG payment, and the MCGR device costs were added to account for the difference in device cost. The total costs for procedures included in the model are shown in Table 3. Unit costs for these procedures, including all DRG, current procedural terminology, and ambulatory payment classification codes and costs, as well as X-ray, intraoperative neurophysiological monitoring, and anesthesia codes and costs, can be viewed in the Supplementary materials.

### Sensitivity analysis

Extensive one-way sensitivity analyses were conducted on a range of model variables to establish how robust the cumulative cost savings were to realistic changes in the boundaries of the key parameters and assumptions of the model. The lower and upper bounds for these parameters are outlined in Tables 1–3 and the Supplementary materials. Two-way sensitivity analyses were also conducted for device failure rate and the months between lengthenings.

### Results

#### Base-case results

Over the 6-year episode of care, MCGR was associated with an estimated 11.2 fewer invasive procedures per patient compared with TGR (MCGR: 3.33; TGR: 14.53). When simulating 1,000 EOS patients over the 6-year episode of care, MCGR was associated with an estimated 270 fewer deep SSIs (MCGR: 80; TGR: 350) and 197 fewer revisions due to device failure compared with TGR (MCGR: 332; TGR: 529).

The cumulative costs for treatment of EOS with MCGR compared with TGR are illustrated in Figure 1. As shown in Figure 1, the higher cost associated with the initial insertion and exchange (at 3.8 years) of MCGR was offset by the repeated TGR surgical lengthenings and associated complications. The cumulative cost for MCGR vs TGR over the 6-year episode of care was cost neutral ($61; MCGR minus TGR) from the US integrated health care delivery system perspective.

### Sensitivity analysis

Extensive sensitivity analyses were conducted. As shown in the one-way sensitivity analysis (Figure 2), the cumulative cost savings of MCGR was most sensitive to MCGR dual rod use, months between TGR lengthenings, TGR lengthenings...
Figure 1 Cumulative cost, per patient (2015 USD).
Notes: This figure illustrates the cumulative costs per patient for treatment of early-onset scoliosis with MCGR compared with TGR over the 6-year episode of care. Exchange surgery conducted at 3.8 years. The cumulative costs presented in this figure are calculated based on total costs, clinical parameters, and medical resource use percentages.
Abbreviations: MCGR, magnetically controlled growing rod; TGR, traditional growing rod; UsD, Us dollars.

Figure 2 One-way sensitivity analysis of cumulative cost savings per patient (2015 USD).
Notes: This figure illustrates how sensitive the primary outcome is to changes in the model parameters. Lowering the parameter is represented in blue, and increasing the parameter is represented in green.
Abbreviations: MCGR, magnetically controlled growing rod; SSI, surgical site infection; TGR, traditional growing rod; USD, US dollars.
that are inpatient (vs outpatient), MCGR cost, and time horizon. The results were less sensitive to the percent of SSIs that are deep infections and years to exchange surgery. When less certain model parameters were varied in the two-way sensitivity analyses, specifically the MCGR device failure rate (Figure 3) and months between MCGR lengthenings (Figure 4), the costs fell within a relatively narrow range when based on realistic clinical scenarios, suggesting that the economic model is robust to plausible parameter values.

In the base-case analysis that evaluated cumulative 6-year costs, the differential was $61; that is, cost neutrality was achieved by the conclusion of the 6-year episode of care. The results were sensitive, however, to the time horizon due to the timing of certain procedures in the process of care, most notably the exchange surgery at 3.8 years. As a result, ~73% of the cumulative costs for MCGR were accrued in year 1 (initial implantation) and year 4 (exchange surgery); these costs were then offset over time.

**Discussion**

Economic models facilitate exploring the extent to which costs of a new intervention may be offset by reductions in other medical costs. The economic model presented in this study demonstrates that the cost impact of MCGR is offset by eliminating repeated TGR surgical lengthenings and associated complications. The cost offsets for MCGR were driven by fewer deep SSIs, less device failures resulting in fewer revisions, and absence of a hospital inpatient stay.
anesthesia, and intraoperative neurophysiological monitoring during MCGR lengthenings. In the US, providers are becoming increasingly at financial risk as bundled payments shift the risk of financial accountability from the payer to the provider.\textsuperscript{28} With the trend toward bundled payments in orthopedics, providers will be at risk for a defined episode of care, including hospital stays, complications, and implant costs.\textsuperscript{21} This cost analysis demonstrates, from a provider perspective, the efficient provision of care with MCGR.

Our analysis differs in several ways from previous analyses of MCGR conducted for the European and the US settings of care.\textsuperscript{11–13} Most notably, our analysis evaluated cumulative costs over the 6-year episode of care (from initial implantation through final fusion) – inclusive of the exchange surgery at 3.8 years for both TGR and MCGR. In addition, our analysis reflected the US practice patterns where the majority (85%) of cases use dual-rod rather than single-rod constructs, and TGR lengthenings are performed in both the hospital inpatient and outpatient settings (with more frail children requiring greater resources such as an intensive care unit stay).\textsuperscript{22} On the other hand, the UK study by Rolton et al,\textsuperscript{12} the French study by Charroin et al,\textsuperscript{11} and the US payer perspective study by Su et al\textsuperscript{13} all demonstrated cumulative cost savings without accounting for the exchange surgery and assumed that TGR lengthenings are performed entirely in the hospital inpatient setting. These differences in modeling approaches may represent variations in either practice patterns or modeling assumptions.

Charroin et al\textsuperscript{11} and Su et al\textsuperscript{13} explain that their time horizons (4 and 5 years, respectively) were selected to accommodate the complete lengthening capacity of MCGR (4.8 cm), not necessarily a full episode of care. After achieving MCGR maximal range of lengthening at 4.8 cm, Su et al\textsuperscript{13} acknowledged that MCGR is likely to require an exchange to accommodate further growth. In the present study at 3 years following initial implantation and prior to the exchange surgery at 3.8 years, MCGR resulted in a cumulative cost savings of $2,943 compared to TGR (Figure 1), which is consistent with the prior research studies that did not account for the exchange surgery. This finding of cumulative cost savings at 3 years following initial implantation of MCGR may also apply to surgeries involving conversions of TGR to MCGR where an MCGR exchange procedure is not anticipated.\textsuperscript{23}

As noted previously, we performed a cost analysis of MCGR compared with TGR for EOS from the US provider perspective, whereas Su et al\textsuperscript{13} performed a similar analysis but from the US payer perspective. We used Medicare payments as a proxy for provider costs, a well-accepted methodology in economic analyses.\textsuperscript{24} On the other hand, Su et al\textsuperscript{13} determined costs using the Kids’ Inpatient Database in the NIS Healthcare Cost and Utilization Project Database. Of note, the database contains hospital charge data (as reflected on a hospital bill), not insurer payments or the actual cost to the hospital for the provision of care to the patient. Given that insurers generally pay less than hospital charges,\textsuperscript{25} it remains unclear to what degree the use of hospital charges may have affected the difference in cumulative costs between TGR and MCGR reported by Su et al.\textsuperscript{13}

Further, in our study, we incorporated a distribution of practice settings (roughly half hospital inpatient and half hospital outpatient) for performing TGR lengthenings based on a multicenter EOS database comprising US institutions,\textsuperscript{22} whereas Su et al\textsuperscript{13} assumed that TGR lengthenings were performed entirely in the hospital inpatient setting in the US. The approximate Medicare reimbursement for TGR lengthenings is $6,000 (when considering both practice settings), compared to the $10,000 in hospital inpatient charges noted by Su et al.\textsuperscript{13} If one takes 60% of the cumulative cost of TGR lengthenings estimated by Su et al,\textsuperscript{13} the cost savings of MCGR reported by Su et al\textsuperscript{13} are diminished; nevertheless, it appears that MCGR would be cost neutral in year 5 from the US payer perspective, which is similar to our results at year 6 from the US provider perspective.

Overall, the study by Su et al\textsuperscript{13} seems to be a “best case” analysis of the potential cost savings associated with MCGR for the treatment of EOS. The UK study by Rolton et al\textsuperscript{12} and the French study by Charroin et al\textsuperscript{11} are perhaps slightly less so but still show cost savings. Our cost analysis by comparison is more conservative. Nonetheless, the trend in all of these studies is that while there is an added expense from the new technology, the cost offsets appear to economically justify the adoption of MCGR. With use of MCGR, there is substantial value from obviating repeat anesthetic and surgical events, as well as avoiding family disruption. The significant yet unquantified clinical benefit – and associated financial benefit – from avoiding repeated surgical TGR lengthenings warrants further investigation.

Limitations
At present, the MCGR literature on device failure is limited to small numbers of patients with a follow-up period of 2 years. Sensitivity analyses were performed on the MCGR device failure rate in light of this limitation. Where data for MCGR were not available from the published literature, conservative assumptions were made by using the same parameter values as for TGR based on TGR clinical studies, in particular the study by Bess et al.\textsuperscript{18} When these less certain MCGR clinical parameters were varied within a plausible range, the
inferences of the model did not change suggesting that the model is robust.

While not a limitation per se, it is worth noting that the model presented is a cost analysis and not a cost-effectiveness analysis. Therefore, similar to previous economic research of MCGR, it has not accounted for, 1) the pain, psychological distress, and compromised HRQoL associated with invasive TGR lengthening surgeries, or 2) the shorter recovery time with MCGR lengthenings, which results in less time away from usual activities for young patients and their families. Therefore, further analyses developed specifically to measure and evaluate HRQoL should be considered for future research.

Conclusion
Cost offsets for MCGR accrue over time and reflect the elimination of repeated invasive TGR surgical lengthenings and their associated complications. Despite the higher up-front cost for insertion of the MCGR implant and later for exchange of the MCGR implant, the cumulative cost of MCGR is offset over the 6-year episode of care from the perspective of the US integrated health care delivery system. The HRQoL gained by MCGR patients and their caregivers is likely to be substantial and warrants further investigation.

Disclosure
This study was sponsored, in part, by NuVasive Specialized Orthopedics. SJA and KS are consultants to NuVasive through their employment at Covance. (As salaried employees of Covance, no direct compensation was received by these authors; payments were made directly to Covance.) BAA receives grant support to his institution from NuVasive. In addition, BAA is a consultant to K2M and NuVasive, holds stock in NuVasive and NociMed, and receives royalties from Depuy Synthes, K2M, and NuVasive. DWP and JBP report no conflicts of interest in this work. The sponsor, NuVasive Specialized Orthopedics, did not participate in the data analysis, interpretation of the results, or the writing of this manuscript.

References


